06.10.15
PCI Synthesis, Inc., a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, has strengthened ties with the Greater Boston life sciences community with the signing of a dozen local biotech and medtech customers.
“This year has been one of tremendous growth for PCI,” said Ed Price, president, PCI Synthesis. “We’ve reached major milestones with customers, products, staff and awards, testament to the quality of our work and our commitment to put the customers first.”
Local partnerships have been a growing trend in the industry and in PCI’s business as well. According to Mr. Price, “Emerging pharma customers prefer the ease and practicality of working locally with partners. There is greater collaboration, a faster buildup of trust and overall better communication when you work with a local partner as compared to a business located somewhere overseas or in a different time zone. The end result offers a better product, saved time, and saved money—tangible benefits that customers appreciate.”
Many of PCI’s newest customers are just a short drive from the company’s Newburyport and Devens facilities, making it easy for customers to see the manufacturing in action and check on the status of their project.
PCI expects the commercialization of two products this year, active ingredients in generic drugs. To meet the demand in new customers and products in the pipeline, the company now stands at more than 110 employees, an increase of 22% over last year. It is actively hiring for a variety of new positions.
Due to this momentum and its growing reputation, PCI Synthesis was recently recognized as a Life Science Leader CMO Leadership Award recipient for the second year in a row in multiple categories. It won regulatory awards for both the midsize pharma and biotech industry sectors. The company has now won the top spot in every category in which the awards are given.
“This year has been one of tremendous growth for PCI,” said Ed Price, president, PCI Synthesis. “We’ve reached major milestones with customers, products, staff and awards, testament to the quality of our work and our commitment to put the customers first.”
Local partnerships have been a growing trend in the industry and in PCI’s business as well. According to Mr. Price, “Emerging pharma customers prefer the ease and practicality of working locally with partners. There is greater collaboration, a faster buildup of trust and overall better communication when you work with a local partner as compared to a business located somewhere overseas or in a different time zone. The end result offers a better product, saved time, and saved money—tangible benefits that customers appreciate.”
Many of PCI’s newest customers are just a short drive from the company’s Newburyport and Devens facilities, making it easy for customers to see the manufacturing in action and check on the status of their project.
PCI expects the commercialization of two products this year, active ingredients in generic drugs. To meet the demand in new customers and products in the pipeline, the company now stands at more than 110 employees, an increase of 22% over last year. It is actively hiring for a variety of new positions.
Due to this momentum and its growing reputation, PCI Synthesis was recently recognized as a Life Science Leader CMO Leadership Award recipient for the second year in a row in multiple categories. It won regulatory awards for both the midsize pharma and biotech industry sectors. The company has now won the top spot in every category in which the awards are given.
